Please find attached the minutes from the Extraordinary General Meeting (EGM) of
EXACT Therapeutics AS held on 24 July 2020. All resolutions were approved as
proposed by the Board of Directors, including  the 1:250 split of the company's
shares and the appointment of EY as auditors.


For further queries, please contact: 


Masha Stromme, Chair +47 93022509
Stig Jarle Pettersen, CFO +47 90960336


EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated,
targeted drug enhancement - with the potential to significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy), infectious
diseases, and neurological conditions. www.exact-tx.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange